RA Capital and Forbion set up new autoimmune biotech with bispecific from Korean startup
Another autoimmune biotech emerged on Tuesday morning with a $100 million Series A.
Navigator Medicines launched with a license to a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
